Progyny (PGNY) Projected to Announce Earnings on Wednesday

Progyny (NASDAQ:PGNY) is expected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.3130 per share and revenue of $340.76 million for the quarter. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. The business had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the business earned $0.19 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, analysts expect Progyny to post $1.25 EPS for the current fiscal year and $1.42 EPS for the next fiscal year.

Progyny Price Performance

Shares of NASDAQ:PGNY traded up $0.51 during trading on Wednesday, hitting $28.23. The company’s stock had a trading volume of 33,867 shares, compared to its average volume of 1,364,386. The company has a 50-day moving average of $26.71 and a 200-day moving average of $24.42. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 3,903 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the transaction, the executive vice president owned 75,816 shares in the company, valued at $1,978,797.60. This trade represents a 4.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Gordon sold 11,500 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares of the company’s stock, valued at approximately $189,768.48. The trade was a 62.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 17,282 shares of company stock valued at $475,790 over the last ninety days. 9.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PGNY has been the subject of several research analyst reports. Weiss Ratings raised shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Citizens Jmp increased their target price on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. Barclays reduced their price objective on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 12th. Finally, Jefferies Financial Group set a $33.00 price objective on Progyny in a research report on Tuesday, September 8th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.36.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.